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Dr	Yiaying	Tan	
Senior	Editor	
Cell	
	
Dear	Dr	Tan,		
	
Re:	Tracking	renal	cancer	evolution	reveals	constrained	routes	to	metastases,	results	from	
the	TRACERx	Renal	study	
I	am	pleased	to	enclose	our	revised	manuscript	on	the	evolutionary	dynamics	of	metastatic	
clear	cell	renal	cell	carcinomas	(ccRCC).	We	would	like	to	thank	reviewers	for	their	constructive	
feedback	and	suggestions	which	have	resulted	in	a	significantly	improved	manuscript.	We	have	
also	 taken	 this	 opportunity	 to	 clarify	 the	 presentation	 of	 both	 text	 and	 figures,	 ensuring	
consistency	throughout.	The	major	changes	to	the	manuscript	are:	
1. We	present	a	meta-analysis	of	the	metastasising	clone	across	three	cohorts	of	primary	
metastasis	 pairs:	 TRACERx	 Renal	 (n=38),	 HUC	 (n=26)	 and	MSK	 (N=34);	 in	 total,	 the	
meta-analysis	is	based	on	580	primary	and	255	metastatic	biopsies	across	98	patients	
with	metastatic	 ccRCC.	 	 This	 is	 the	 largest	 study	of	 its	 kind	 to	 date,	 offering	 broad	
insight	into	the	diverse	spectrum	of	modes	of	progression	from	primary	to	metastatic	
disease.	We	identify	the	selection	of	loss	of	9p	as	a	potent	driver	of	both	metastases	
and	 mortality	 risk,	 even	 after	 adjustment	 for	 established	 clinically	 prognostic	
indicators	(HR=7.7,	p=0.0014).	
2. We	stratified	the	mode	of	disease	progression	as	“rapid”	or	“attenuated”	according	to	
the	 metastatic	 disease	 tempo	 and	 show	 that	 these	 clinical	 phenotypes	 are	
underpinned	by	distinct	evolutionary	features.	
Cover Letter
		 2	
3. In	 the	previous	version	of	 the	manuscript	we	presented	one	case	 sampled	at	post-
mortem	and	in	the	revised	version	we	present	an	additional	case;	adding	to	a	total	of	
9	primary	and	81	metastatic	regions	obtained	at	post-mortem.	Critically	the	two	cases	
illustrate	the	contrasting	patterns	of	progression	we	observed	in	the	TRACERx	Renal	
cohort	 from	 a	 punctuated	 evolution	 in	 the	 primary	 tumour	 and	 rapidly	 spreading	
metastases	in	a	patient	who	survived	6	months;	to	a	primary	tumour	which	evolved	
gradually	 into	multiple	 subpopulations	 in	 which	metastases	 were	 seeded	 over	 the	
course	of	17	years.		
4. In	an	exploratory	analysis,	we	show	that	in	the	context	of	intravascular	tumour	growth	
seeding	from	the	ancestral	clone	 is	associated	with	 improved	clinical	outcome;	that	
lymph	nodes	are	seeded	by	the	same	primary	tumour	clones	as	visceral	metastases;	
and	that	pancreatic	metastases	 lack	the	genomic	features	that	confer	an	aggressive	
clinical	phenotype.	Although	descriptive	in	nature	these	findings	reconcile	a	number	
of	clinical	observations	in	ccRCC	
	
Overall,	 we	 have	 emphasised	 the	 preliminary	 nature	 of	 our	 results	which	will	 be	 explored	
further	in	the	ongoing	analyses	in	TRACERx	Renal	and	PEACE	studies.	Nevertheless,	our	data	
provide	 the	 first	 large-scale	 resolution	 of	 the	 metastasising	 clones	 and	 offer	 a	 biomarker	
opportunity	in	ccRCC.	
We	have	included	our	point	by	point	rebuttal	and	actions	in	response	to	reviewer	comments	
in	a	separate	document.		
	
Thank	you	for	your	consideration	
	
	
Yours	sincerely,		
	
	
	
Charles	Swanton	
	
On	behalf	of	the	TRACERx	Renal	consortium	
	
	
	
The previous version of this paper was not sent out for peer review. 
 
Response to Reviewers
 Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal 
Samra Turajlic1,2*, Hang Xu1*, Kevin Litchfield1*, Andrew Rowan1*, Tim Chambers1*, Jose I 
Lopez3*, David Nicol4*, Tim O’Brien5*, James Larkin2* Stuart Horswell6, Mark Stares1,2, Lewis Au2, 
Mariam Jamal-Hanjani7, Ben Challacombe5,  Ashish Chandra8, Steve Hazell9, Claudia Eichler-Jonsson1, 
Aspasia Soultati10, Simon Chowdhury10, Sarah Rudman10, Joanna Lynch2, Archana Fernando5, Gordon 
Stamp11, Emma Nye11,  Faiz Jabbar1, Lavinia Spain2, Sharanpreet Lall10, Rosa Guarch12, Mary Falzon13, 
Ian Proctor13, Lisa Pickering2, Martin Gore2, Thomas B.K. Watkins1, Sophia Ward1,7, Aengus Stewart3, 
Renzo DiNatale14, Maria F. Becerra14, Ed Reznik15, James J. Hsieh16, Todd A. Richmond17, George F. 
Mayhew17, Samantha M. Hill18, Catherine D. McNally18, Carol Jones18, Heidi Rosenbaum17, Stacey 
Stanislaw18, Daniel L. Burgess17, Nelson R. Alexander18, Charles Swanton1,7,19 on behalf of PEACE and 
TRACERx Renal consortia 
 
* These authors contributed equally 
Correspondence: Charles Swanton  
Lead contact: Charles Swanton                                                                   
Translational Cancer Therapeutics Laboratory          
The Francis Crick Institute, 1 Midland Rd                                                                
London NW1 1AT, UK 
Charles.swanton@crick.ac.uk 
 
Affiliations 
 
1. Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, 
UK 
2. Renal and Skin Units, The Royal Marsden Hospital NHS Foundation Trust, London, SW3 6JJ, UK 
3. Department of Pathology, Cruces University Hospital, Biocruces Institute, University of the 
Basque Country, Barakaldo, Spain 
4. Urology Centre, Guy's & St Thomas' NHS Foundation Trust, London, UK 
5. Department of Urology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK 
Manuscript
 6. Department of Bioinformatics and Biostatistics, The Francis Crick Institute, London NW1 1AT, 
UK 
7. Cancer Research UK Lung Cancer Centre of Excellence London and Manchester, University 
College London Cancer Institute, London WC1E 6DD, UK 
8. Department of Cellular Pathology, Guy's & St Thomas' NHS Foundation Trust, London SE1 7EH, 
UK 
9. Department of Pathology, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK 
10. Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK 
11. Experimental Histopathology Laboratory, The Francis Crick Institute, London NW1 1AT, UK 
12. Department of Pathology, Complejo Hospitalario de Navarra, Pamplona 31008, Spain 
13. Department of Pathology, University College London Hospitals, London, WC1E 6DE, UK 
14. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, NY, USA  
15. Centre for Molecular Oncology, Memorial Sloan Kettering Cancer Center, NY, USA 
16. Molecular Oncology, Department of Medicine, Siteman Cancer Center, Washington 
University, St. Louis, MO, USA 
17. Ventana Medical Systems, Tucson, AZ 85755 
18. Roche Sequencing Solutions, Madison, Research & Development, Madison, WI  53719, USA  
19. Department of Medical Oncology, University College London Hospitals, London, NW1 2BU, UK 
 
 
 
 
 
  
 Summary 
 
Clear-cell renal cell carcinomas (ccRCC) exhibit a broad range of metastatic phenotypes, which have 
not been systematically studied to date. Here we analysed 589 primary and 336 metastatic biopsies, 
across 100 metastatic ccRCC patients, including two cases profiled in a post-mortem setting. 
Metastatic competence was afforded by chromosome complexity and we identify 9p loss as a highly 
selected event driving metastasis and ccRCC related mortality (HR=7.7, p=0.0014). Distinct patterns of 
metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded 
by primary tumours of monoclonal structure. By contrast we observe attenuated progression in cases 
characterised by high primary tumour heterogeneity, with metastatic competence acquired gradually 
and initial progression to solitary metastasis. Finally, we observe early divergence of primitive 
ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.  
  
 Introduction  
Large-scale sequencing initiatives such as the cancer genome atlas (TCGA) and the international cancer 
genome consortium (ICGC) have profiled thousands of primary tumours, across many cancer types. 
Large-scale studies of metastases have been limited (Robinson et al., 2017; Zehir et al., 2017), and, 
critically have not included matched primary tumours. Understanding evolution of metastatic disease 
requires simultaneously analysis of the primary tumour in order to distinguish clones with and without 
metastatic potential. To date, a limited a number of primary-metastasis(es) pairs have been analysed 
retrospectively (Shah et al., 2009; Campbell et al., 2010; Yachida et al., 2010; Ding et al., 2010; Haffner 
et al., 2013; Bashashati et al., 2013; Lee et al., 2014; Gerlinger et al., 2014; Brastianos et al., 2015; 
Gundem et al., 2015; Schwarz et al., 2015; McPherson et al., 2016; Zhao et al., 2016; Casuscelli et al., 
2017; Yates et al., 2017). 
The well-established molecular landscape of primary clear cell Renal Cell Carcinoma (ccRCC) defined 
by the loss of 3p and VHL mutations/methylation as early events, provides an excellent model for 
study of cancer evolution.  Metastatic ccRCC, with its variable clinical presentation and natural history, 
is a compelling model for understanding the clonal evolution of metastases. CcRCC metastases spread 
by both lymphatic and haematogenous routes and colonise a range of sites including, lung, bone, liver, 
brain, pancreas, adrenal, parotid and thyroid glands, as well as muscle, skin and soft tissue (Bianchi et 
al., 2012). Liver metastases confer a worse prognosis (McKay et al., 2014), while low volume lung 
metastases are associated with a more indolent disease course. Some ccRCCs also grow intravascularly 
forming a tumour thrombus in the renal vein/inferior vena cava. Approximately one third of patients 
have metastases detected at pre-operative screening or surgery, termed synchronous metastases. Up 
to 50% develop metastases after the removal of the primary tumour (at least 3 months and as late as 
30 years after primary surgery), termed metachronous metastases. The spatial distribution of 
metastatic disease in ccRCC ranges from solitary (a single metastasis in a single location), to oligo 
 (limited in number and location; usually defined as ≤5 or ≤3 metastases (Weichselbaum and Hellman, 
2011)), to widespread (multiple metastases in multiple sites). 
The clinical relevance of solitary and oligometastases is that they can be managed by local strategies 
(surgery, stereotactic radiotherapy and other ablative therapies) rather than systemic therapy. For 
metachronous metastases the outcome of this approach generally depends on the time interval since 
the initial surgery (Dabestani et al., 2014). For patients presenting with synchronous solitary or 
oligometastases, a multi-modal strategy that involves cytoreductive nephrectomy (removal of the 
primary tumour), metastasectomy (complete resection of the metastasis) and systemic therapy can 
achieve an improved outcome (Bex et al., 2016).  However, 20% of patients progress as early as one 
month following surgery (A. Bex, 2017), sometimes failing to receive systemic therapy due to rapid 
disease pace (Kutikov et al., 2010). Thus, there is a pressing need to understand which patients 
harbour more widespread occult metastases and therefore do not benefit from surgery. 
In our analyses of 100 primary ccRCCs in the prospective longitudinal cohort study, TRAcking renal cell 
Cancer Evolution through Therapy (TRACERx Renal, clinical trials no NCT03226886) we used conserved 
patterns of evolution to classify tumours into 7 distinct evolutionary subtypes (Companion paper, 
Turajlic et al., 2018). Primary tumours with low intratumour heterogeneity (ITH) and a low fraction of 
the tumour genome affected by somatic copy number alterations (SCNAs), had an overall low 
metastatic potential. Primary tumours with high ITH were associated with an attenuated pattern of 
progression, whereas primary tumours with low ITH but elevated SCNAs were associated with a rapid 
progression at multiple sites (Companion paper, Turajlic et al. 2018). A pre-defined endpoint in the 
TRACERx Renal study was to explore the contribution of subclonal dynamics to ccRCC metastasis. To 
distinguish metastasis-competent from incompetent clones, and examine the routes and timing of 
metastases across multiple anatomic sites, we analysed 463 primary and 169 matched metastatic 
regions from a subset of 38/100 patients in the TRACERx Renal Cohort (Companion paper, Turajlic et 
al., 2018); 80 primary regions and 54 metastatic regions in an extension cohort of 26 patients; 34 
 matched primary-metastasis pairs in a further validation cohort; and finally, 9 primary and 81 
metastatic regions obtained at post-mortem in 2 patients. In total, we analysed 100 primary-
metastasis pairs derived from 589 primary and 336 metastatic biopsies.  
Results 
Overview of the cohorts under study 
ccRCC tumours exhibit a variety of progressive phenotypes including invasion of the peri-renal and 
renal sinus fat (T3a), direct invasion through the renal capsule (Gerota’s fascia) and into the adrenal 
gland (T4), intravascular tumour growth (T3a-T3c); and lymph node (N1/N2) and visceral metastases 
(M1), including indirect spread to the adrenal gland. In 38 patients whose primary tumours were 
profiled in the TRACERx Renal cohort (Table S1A), we profiled multiple regions from matched tumour 
thrombi, lymph node or visceral metastases using a bespoke gene panel (STAR Methods: Driver 
Panel).  
The overall number of driver events (mutations and SCNAs as presented in Figure 1A) was lower in 
metastases (mean=9), compared to primary tumours (mean=12, p=0.05, adjusted for the varying 
number of profiled regions, STAR methods) (Figure 1A). Consistent with evolutionary bottlenecking, 
metastases were significantly more homogeneous (proportion of clonal variants = 0.87) compared to 
primary tumours (proportion of clonal variants = 0.33, p=6.6x10-13, adjusted for the varying number 
of profiled regions, Figure 1B). Across the 56 primary-metastasis pairs 456 driver events were shared 
between primary and metastases, 230 were private to primary tumours and 39 driver events were 
private to metastases (Figure 1C). Driver phylogenies were reconstructed to infer clonal relationships 
between primary tumours and metastases (STAR methods).  
The TRACERx Renal cohort was enriched for synchronous metastases (Figure 1D), and to widen our 
investigation we analysed two additional cohorts. Using the Driver Panel (STAR methods) we multi-
region profiled the “HUC” (Hospital Unversitario Cruces) cohort of archived formalin fixed paraffin 
embedded (FFPE) primary ccRCCs and matched synchronous (6 cases), and metachronous metastases 
 (23 cases) (STAR methods; Table S1B).  We successfully profiled 80 primary tumour regions and 54 
metastatic regions in 26 patients (two patients contributed multiple metastases, Figure S2). For the 
second cohort, “MSK” (Memorial Sloane Kettering), we re-analysed the sequencing data from a study 
of primary-metastasis pairs (Becerra et al., 2017) (STAR methods), to obtain both mutational and 
SCNA events in a total of 34 cases, including 19 synchronous, and 15 metachronous metastases (Table 
S1C, Figure S2). As expected, we noted a difference in the overall frequency of driver events in the 
HUC and MSK cohorts owing to the increased sensitivity for detecting subclonal alterations in the 
TRACERx Renal cohort (Table S2). There was a wide temporo-spatial representation of metastases 
across the three cohorts encompassing 18 distinct metastatic sites (Figure 1E), and presenting 0-17 
years after the removal of the primary tumour (Tables S1A-C). Finally, we profiled a wide range of 
metastatic tissues sampled at post-mortem in the context of the Posthumous Evaluation of Advanced 
Cancer Environment (PEACE) study (NCT03004755) in two cases of metastatic ccRCC (Table S1A). 
 
Characterisation of the metastasising clone(s)  
 
Taking advantage of the dense spatial sampling and phylogenetic reconstruction conducted in the 
TRACERx Renal cohort (Companion paper, Turajlic et al. 2018), we analysed the progression of 
individual clones from primary to metastatic sites. Across the 38 patients we observed 250 distinct 
tumour clones which we categorised into three groups based on the evidence of selection in the 
metastasis/metastases: i) clones that are not selected (“not selected”, n=129 clones, defined as 
subclonal in the primary and absent in metastasis), ii) clones that are maintained (“maintained”, n=38 
clones, defined as the most recent common ancestor (MRCA) clones, clonal in both primary and 
metastasis), iii) clones that are selected (“selected”, n=83 clones, defined as subclonal in the primary 
and clonal in metastasis; or absent in the primary and present in metastasis) (Figure 2A, STAR 
Methods). Clones that were private to the metastasis may have evaded detection as a minor subclone 
in the primary tumour, or arisen de novo in the metastasis. The ability to differentiate the clones that 
appear to be selected versus not on a matched patient/tumour specific background across the whole 
 cohort, allowed us to characterise the features associated with metastasis. We observed no difference 
in the number of non-synonymous mutations between the two groups (based on Driver Panel profiling 
median value = 4 for both, p=0.5295), however wGII was significantly elevated in selected clones 
(median “selected” = 0.29 vs “not selected” = 0.17, p<0.001, Figure 2B). This was further supported 
by ploidy (determined by regional fluorescence activated cell sorting, FACS, STAR methods) also being 
significantly elevated in selected clones (mean DNA index “selected” = 1.29, “not selected” = 1.16, 
p<0.001, Figure 2B). Multi-region immunohistochemistry staining for Ki67 (STAR Methods) 
demonstrated higher proliferation index in the clones that were selected, compared to those that 
were not (median Ki67 +40% higher in selected versus non-selected clones, p=0.0317, Figure 2B). 
Finally, we observed increased allelic imbalance at the human leukocyte antigen (HLA) locus in 
selected versus non-selected clones (HLA allelic imbalance observed in n=12 “selected”, versus n=2 
“not selected” clones, Table S3), in concordance with the findings in non-small cell lung cancer 
(McGranahan et al., 2017).  
Next, we considered the individual driver events, mutational or SCNAs, that are selected during 
progression to metastasis, by comparing, for each event, the proportion of times it was found in 
“selected” versus “not selected” clones (Figure 2C). We conducted this analysis across TRACERx Renal 
(n=38), HUC (n=26) and MSK (n=34) cohorts, providing a total dataset of 98 matched primary-
metastasis pairs. Significance was calculated by comparing event selection proportions, to null 
background rates as observed across all passenger events in each cohort (STAR Methods). "Selected” 
event frequencies were compared to "not selected", and one event was found to be significantly 
enriched in "selected" clones: loss of chromosome 9p21.3 (p=0.0026, padj<0.1 after adjustment for 
multiple testing, Figure 2C). We also note loss of chromosome 14q31.1 reached significance in the 
meta-analysis before correction for multiple testing (p=0.0275, padj=0.303), suggesting this and other 
driver events may also contribute to metastasis. We acknowledge the risk of illusion of clonality (i.e. 
subclonal events appearing clonal within a single region of a primary tumour) limited our power to 
detect metastatic selection in the MSK, and to a lesser extent HUC, cohorts. For example, 53% of 
 events in the TRACERx Renal cohort were subclonal, compared to only 31% in HUC and 11% in MSK 
cohorts. 
Metastatic ccRCC has a variable spectrum of survival outcomes, with overall survival (OS) times 
ranging from short (<6 months), to prolonged (>5 years). Accordingly, we conducted OS analysis for 
the two events that were enriched in metastasising clones (P<0.05 from Figure 2C), to understand if 
they were also driving early ccRCC-related mortality, based on their presence/absence within the 
metastasising clone(s) of each case. OS data were not available for the MSK cohort. Hazard ratios (HR) 
were observed as follows (Figure 2D): 9p loss (HUC cohort HR=7.7, [2.8-20.8] 95% confidence interval, 
TRACERx cohort HR=Infinity [no events in wild type group], p=0.0014 log-rank test across both cohorts, 
with study included as a term in the cox model) and 14q loss (HUC cohort HR=1.5, [0.6-3.9] 95%, 
TRACERx cohort HR=2.0, [0.5-8.2], non-significant). We note the strong association between reduced 
survival and 9p loss in the metastasising clone remained significant after correction for known clinical 
variables (p=0.046, adjusted for stage, grade and study) (Figure 2E). 9p deletions have been reported 
to confer a poor prognosis (El-Mokadem et al., 2014; La Rochelle et al., 2010), however the hazard 
ratios in our analysis (HR=7.7 and HR=infinity) are higher than reported in those studies (HR=4.3 (El-
Mokadem et al., 2014), HR=1.7 (La Rochelle et al., 2010)), which may reflect the greater sensitivity of 
profiling events within the metastasising clones.  
Evolution of tumour thrombus 
 
Intravascular tumour growth and formation of tumour thrombus (TT) is observed in ~15% of ccRCCs 
either in the renal vein (level I), extending to the infrahepatic inferior vena cava (IVC) (level II), 
retrohepatic or suprahepatic IVC (level III) or reaching the right atrium (level IV) (Psutka and Leibovich, 
2015) (Figure 3). Untreated TT is associated with a poor outcome (Reese et al., 2013), but aggressive 
surgical management involving a thrombectomy can result in long-term survival in some patients 
(Psutka and Leibovich, 2015). In the TRACERx Renal cohort 33/100 ccRCC cases presented with venous 
tumour extension (Companion paper, Turajlic et al., 2018), only one of which was classified as a “VHL 
monodriver” tumour which harboured 9p loss (K253, Figure 3). Median survival in patients with TT 
 was 17.8 months (Table S1D) with three patients dying within 6 months of surgery due to disease 
progression (K328, K263, K390); classified as “multiple clonal” driver (2 cases) and “VHL wt” (1 case) 
subtypes (Table S1D).   
In 24/33 cases we successfully profiled the TT along its length (Table S1D), and reconstructed driver 
phylogenies to infer the clonal relationship between primary tumour and the intravascular tumour 
extension (Figure 3). The TT was seeded directly by the most recent common ancestor (MRCA, the 
clone which harbours the full complement of alterations common to all the clones in the tumour; 
denoted by the first node in the phylogenetic tree) in ten cases (K239, K118, K250, K207, K059, K167, 
K276, K107, K253, K191; Figure 3). In other cases, the TT emerged from the more advanced subclones 
in the primary tumour, which harboured additional drivers, including 9p loss. Cases where the TT was 
seeded by the MRCA, suggesting intravascular growth was an early event, had an improved clinical 
outcome compared to the cases where late emerging clone seeded the TT (Figure S3A). Whilst most 
primary tumours had evidence of ongoing evolution, tumour thormbi harboured limited additional 
alterations (94.9% of TT events were shared with primary). Consistent with the propensity of TT to 
progress rapidly (Woodruff et al., 2013), we observed an elevated proliferation index within primary 
tumours presenting with TT compared to those without (P = 0.00095, Figure S3B). Thus, the lack of 
fixation of new driver events in TTs may be due to their rapid extension and/or limited selective 
pressure in the intravascular space.  
An interesting biological and clinical question relates to the ability of TT to act as a source of other 
metastases, and in this context, we profiled six patients with venous tumour extension and concurrent 
lymph node and/or visceral metastases (Figure S3C). In some cases, distinct clones in the primary 
tumour seeded the TT and the metastasis (K326 and K390; Figure S3C). Consistent with the worse 
prognosis conferred by lymph node involvement in ccRCC, in K390 the lymph node seeding clone 
harboured 9p loss while the TT clone did not. The same primary clone seeded both TT and metastasis 
in K096 and K427 (Figure S7); whilst in K107 and K263 (Figure S7) the metastasising clone appeared 
to first seed the thrombus, and then lymph node and adrenal sites, respectively, suggesting TT may 
 act as a reservoir of metastases, consistent with the poor outcomes of untreated thrombus (Reese et 
al., 2013). The alternative explanation is that all the sites, including TT were seeded by a clone which 
evaded detection in the primary tumour.  
Evolution of progressive disease 
Within the 38 TRACERx Renal primary-metastasis cohort 25 patients developed progressive disease. 
The clinical outcomes in this group were variable, with overall survival time ranging from 1.5-54.4 
months (Table 1A).   Given that cytoreductive nephrectomy and metastasectomy are performed to 
achieve longer disease-free survival, we considered the evolutionary features of cases that progressed 
rapidly (i.e. multiple sites of disease progression within 6 months of surgery) versus those with 
attenuated progression (i.e. single site progression <6 months; or multi-site progression >6 months), 
capturing both the speed and the extent of metastatic spread (Table S1E, Figure 4A). One patient 
(K328) died from operative complications and was excluded from the analysis. Eight cases were 
classified as having “rapid progression”: K376, K326, K263, K107, K153, K446, K390 and K066 (Figure 
4A).  This group was enriched for “multiple clonal driver”, “VHL wild type” and “BAP1 driven” 
evolutionary subtypes (Figure 4B) and associated with lower ITH and elevated wGII relative to the 
cases with attenuated progression (Figure 4C). All primary tumours in this group harboured loss of 9p 
(Figure 4A). They were more likely to progress to liver metastases (6/8) compared to cases in the 
“attenuated progression” group (1/16) (p=0.0013), and had a short overall survival (Figure 4A). 
Particularly notable in this group was case K153 in which lymph node and lung metastases were 
seeded from the same “BAP1 driven” subclone, which had high WGII and harboured 9p loss, while the 
competing “PBRM1-->SETD2” subclone failed to metastasise (Figure S4). 
16 cases were classified within the “attenuated progression” group: K379, K096, K208, K071, K243, 
K206, K520, K180, K029, K228, K427, K253, K229, K386, K276, K280 (Figure 4A). This group was 
enriched for “PBRM1SETD2”, “PBRM1PI3K”, “PBRM1SCNA” and “VHL monodriver” 
evolutionary subtypes, with the primary tumours were characterised by higher ITH index and lower 
 wGII, as compared to the “rapid progression” group (Figure 4C). Disease progression interval was 
longer and often limited to a single metastatic site. Consequently, in some patients, metastatic disease 
was successfully controlled with further surgery (K029) or radiotherapy (K096, K228, K208, K243), 
consistent with the lack of other occult metastases. For example, case K029 (“PBRM1->PI3K”) 
presented with spatially separate bone metastases three years apart. The metastasising clone 
harboured a PBRM1 mutation, but not 9p loss (Figure S4).  Thus, although ITH is associated with 
metastatic disease, the pattern of metastases suggests a reduced metastatic efficiency, possibly due 
to increased clonal competition. This observation is consistent with the notion that heterogenous 
tumours harbour clones with a wide range of metastatic competence. 
Evolution of latent metastases 
 
We compared the time from primary tumour to metastasis, by tissue site, across the combined 
TRACERx/HUC/MSK cohorts. In keeping with the known modes of late recurrence in ccRCC, we 
observed the pancreatic metastases to have the longest time to presentation (median 15 years, 
compared to 3 years for all other tissue sites, Figure 5A). Intriguingly, pancreatic metastases were 
found to have significantly lower wGII, as compared to all other metastatic tissue sites (p=0.0489, 
Figure 5B). A shared clonal ancestry was confirmed between primary and metastatic sites in all 3 
pancreatic metastasis cases, and we observed a strikingly low number of additional driver alterations 
in pancreatic metastases, despite the extended latency time (Figure 5C). In the case of SP006, the 
pancreatic metastasis occurred 17 years after the primary tumour was resected, and the latent clone 
mapped directly back to the founding MRCA clone, suggesting early divergence of a primitive ancestral 
clone. Similarly, in SP023, a case with pancreatic metastasis at 15 years, the latent clone derived from 
the primary MRCA and only acquired one additional driver mutation in MTOR (Figure 5C, Figure S5). 
Finally, SP058 presented with pancreatic metastasis at 8 years, with a single additional driver event 
(SETD2 mutation) in metastasis, while we detected alternative subclones with a greater number of 
driver events in the primary tumour (Figure 5C). The seeding by the ancestral clone and the lack of 9p 
loss suggests that the pancreas may be a more permissive metastatic niche for ccRCC. The reasons for 
 the characteristic latency of pancreatic metastases remain unknown, but are likely to involve 
interactions with the tumour microenvironment, the immune system and altered epigenetic states 
(Giancotti, 2013).  
 
Spatial resolution of metastases through post-mortem sampling  
To explore the clonal dynamics of multiple metastases we sampled them at post-mortem in two cases 
(Table S1A, Figure 6) through the PEACE study (NCT03004755). Case K548 presented with a primary 
ccRCC which had already disseminated to multiple sites including adrenal, loco-regional and 
mediastinal lymph nodes, liver, and pleura (Table S1F). All disease sites, including the primary tumour, 
were sampled at post-mortem (Figure 6A). Clonal mutations were detected in VHL, PBRM1 and SETD2 
genes, and accordingly this case was categorised as a “multiple clonal driver” subtype. The primary 
tumour had low ITH and high wGII, and all 13 metastatic sites sampled were seeded by the dominant 
clone which was characterised, in addition, by 9p loss Figure 6A). We note this patient progressed 
rapidly through two lines of systemic therapy and died six months after the diagnosis of ccRCC (Table 
S1F). The evolutionary features of the primary tumour are in keeping with those we observe in the 
TRACERx Renal cases with “rapid progression” (Figure 4A).  
In case K489 the patient presented with a primary ccRCC and underwent a nephrectomy with curative 
intent (Figure 6B). 7 years following surgery two pancreatic metastases were detected on imaging and 
the patient underwent a complete metastasectomy (Table 1F, Figure 6B). 4 years later they presented 
with lymph node and lung metastases (Figure 6B). They received multiple lines of systemic therapy, 
subsequently developing metastases at additional sites including liver and bone, and succumbing to 
their disease 17 years after the original diagnosis (Table 1F, Figure 6B). We obtained fresh samples at 
post-mortem from multiple lymph node sites, liver, lung, and contralateral kidney metastases; and we 
accessed the primary tumour and the resected pancreatic metastases from archived FFPE material. 
The primary tumour harboured a clonal VHL mutation and 3p loss, and a subclonal PBRM1 and 
 multiple SETD2 mutations, indicating parallel evolution. These features were consistent with the 
“PBRM1SETD2” evolutionary subtype (Companion paper, Turajlic et al., 2018). In accordance with 
our observations in the TRACERx renal cohort (Figure 4), the pattern of disease spread was consistent 
with “attenuated progression”. The two pancreatic metastases were seeded by separate clones 
(indicating potentially distinct waves of metastatic spread) neither of which harboured 9p loss . By 
contrast, subsequent metastases to the lymph nodes, liver, lung and kidney were seeded by an 
advanced clone harbouring additional SCNA events, including loss of 9p.  
Discussion 
 
We present an integrated analysis of 580 primary and 255 metastatic biopsies across 98 patients with 
metastatic ccRCC, in addition to the first report of two ccRCC cases profiled in a post-mortem setting. 
To our knowledge this is the largest study of its kind to date, offering broad insights into the diverse 
spectrum of modes of progression from primary to metastatic disease. A key objective of the TRACERx 
Renal study is to reduce sampling bias and provide clonal resolution of the primary tumour, such that 
the metastasis-seeding clones can be distinguished from metastasis incompetent clones more reliably. 
Clonal resolution facilitates an improved understanding of the genomic events, and broader clonal 
characteristics, that drive metastasis and mortality risk. In addition, the wide range of metastatic 
tissue sites sampled in this study allows detailed analysis of the varying metastatic phenotypes in 
ccRCC. 
First, in characterising metastases, we show profound evidence of evolutionary bottlenecking, with 
metastatic sites being both more homogeneous (median proportion of clonal variants = 0.87) and 
harbouring fewer somatic alterations (median=9), compared to their matched primary tumours (0.33 
and 12). Furthermore, only a minority of driver events (5.4%) were found to be private (or de novo) in 
metastases, indicating that the majority of driver diversity accumulated at the primary tumour site, 
which then serves as the substrate for selection of metastasis-competent populations.  Tumour clones 
which were “selected” and progressed from primary to metastatic sites of disease were characterised 
by elevated levels of somatic copy number alterations, increased proliferation and evidence of 
 immune evasion (in the form of HLA LOH), but not by increased SNV/INDEL counts. 9p loss was found 
to be a potent driver of both metastasis and ccRCC mortality risk, even after adjustment for 
established clinically prognostic indicators. Loss of 14q also showed a trend towards significance, and 
taken together these two events represent hallmark genomic alterations in ccRCC metastasis (overall 
36 of 38 TRACERx Renal cases had loss of at least one of these chromosome arms). Furthermore 71% 
(n=27) of the metastatic cases in the TRACERx renal cohort had loss of both 9p and 14q, compared to 
only 35% (n=22) of cases without metastatic disease at presentation (n=62, Companion paper, Turajlic 
et al., 2018), suggesting these events interact to drive metastatic risk. While investigation of functional 
mechanisms is beyond the scope of this study, we note that p16 (encoded by CDKN2A on 9p) has been 
shown to modulate VEGF expression via its interaction with HIF-1alpha, encoded by HIF1A on 14q 
(Zhang et al., 2010). Critically, in the context of their potential utility as biomarkers both 9p and 14q 
loss were predominantly subclonal in our multi-regional analysis of primary ccRCC (Companion paper, 
Turajlic et al., 2018) and may be missed by single biopsy approaches. 
 
Secondly, our analyses highlight distinct modes of metastatic dissemination (Figure 7). In primary 
tumours characterised by low ITH and high wGII, metastatic competence is acquired within the most 
recent common ancestor, which drives rapid dissemination, leading to surgical failure, poor response 
to systemic therapy and early death from disease. These observations are consistent with the 
presence of occult micrometastases at the time of surgery.  The multiclonal driver case K548, 
examined at post-mortem, is an exemplar of the disseminated metastatic seeding from such tumours. 
In this context, we note that these tumours are a minority in the TRACERx Renal cohort which was 
weighted towards operable patients; hence low ITH / high wGII pattern may be prevalent in patients 
who are deemed inoperable. Acquisition of the metastatic potential at the early stage of tumour 
evolution has been reported in pancreatic (Notta et al., 2016) and breast cancers (Gao et al., 2016) as 
well as uveal melanoma (Field et al., 2018). These observations are consistent with the tendency of 
 some tumours to metastasise rapidly and improving outcomes in such cases presents a significant 
challenge. 
We observed a contrasting phenotype in primary tumours characterised by high ITH and “attenuated 
progression” (Figure 4). Metastatic competence was acquired gradually and was limited to certain 
subpopulations in the primary tumour at the time of surgical resection. The clinical course was 
characterised by an initial solitary or oligometastatic pattern, with metastatic capacity increasing over 
time resulting in more efficient and widespread metastases, as exemplified by case K489. The marked 
latency of metastases in case K489 that may have been mediated by effective immune surveillance, a 
notion supported by the subsequent disease control with interferon.  Our observations in this group 
underpin the significance of cytoreductive nephrectomy and removal of an “evolutionary sink of 
diversity” (Gerlinger et al., 2012) in minimising the risk of future metastatic seeding from evolving 
primary tumours harbouring clones of variable metastatic potential. We note that the evolutionary 
trajectories in this group are underpinned by PBRM1 alterations, in keeping with the observation by 
Brugorolas and colleagues that loss of PBRM1 expression is associated with an increased risk of 
metastasis but not with decreased survival (Joseph et al., 2016). Further OS analysis in larger 
metastatic cohorts will be required to comprehensively contrast the drivers of metastasis from the 
drivers of early mortality. 
In an exploratory analysis of intravascular tumour growth, we observe that TT is associated with 
improved prognosis when seeded from the ancestral clone. In this context, the TT conceivably formed 
shortly after the clonal sweep in the primary tumour, rapidly ascending through the IVC, leading to 
clinical diagnosis (majority of patients presented with symptoms). This notion is consistent with  the  
fact TT is not prognostic in the absence of nodal or metastatic disease (Wszolek et al., 2008) and that 
thrombectomy can be curative. In contrast to primary tumours presenting with TT, isolated lymph 
node involvement portends an extremely poor prognosis in ccRCC, significantly worse than in other 
solid tumour types  (Gershman et al., 2017). We observe that lymph node metastases are 
characterised by similar levels of wGII compared to distant metastases (no significant difference, 
 P=0.21) and frequently harbour 9p loss (21/22 cases), indicating that lymphatic and haematogenous 
spread require comparable metastatic competence. Our observations contrast the divergent lymph 
node/distant metastasis patterns reported in other tumour types (Brastianos et al., 2015; Yates et al., 
2017);  however, are consistent with the frequent presentation of lymph node metastases with 
visceral metastases and the lack of therapeutic benefit from lymph node clearance (Bhindi et al., 
2018).  Finally, in our limited analyses of late recurrences in the pancreas (4 cases) the metastasis-
establishing clone diverged early from the primary tumour and harboured fewer additional events, 
consistent with protracted latency. The metastasising clones lacked 9p loss, suggesting that less 
aggressive clones establish pancreatic metastasis in isolation in keeping with the excellent clinical 
outcome in these patients.   
In summary, we demonstrate that the fitness attribute common to metastases and tumour thrombus-
seeding (sub)clones is chromosomal complexity. Chromosome level alterations that simultaneously 
affect the expression of 100s of genes (Santaguida and Amon, 2015) can support the complex 
metastatic cascade, by altering many functional phenotypes and potentially impacting immune 
evasion (Davoli et al., 2017). The onset of chromosomal complexity in ccRCC provides a permissive 
genomic background for selection of 9p loss, previously linked to poor outcomes (El-Mokadem et al., 
2014; Klatte et al., 2009; La Rochelle et al., 2010).  While preliminary in nature, our collective 
observations point to the deterministic nature of the ccRCC evolutionary subtypes and their 
association with the mode and tempo of metastatic progression. The “rapid progression” group has 
echoes of  the punctuated equilibrium model of rapid speciation events (Eldredge and Gould, 1997) 
and subsequent clonal stasis. In contrast, the evolution of the “attenuated progression” group is 
analogous to Darwin’s phyletic gradualism. Continuing longitudinal and post-mortem sampling 
opportunities in the TRACERx Renal and PEACE studies aim to address this question.  
In conclusion, evolutionary classification of tumours could serve as an important biomarker for 
stratification of patients for surgical intervention (e.g. cytoreductive nephrectomy/metastasectomy) 
in the presence of metastatic disease; to aid management of patients following surgery with curative 
 intent, including decisions on surveillance schedule and adjuvant therapy; and in the context of active 
surveillance programme at the earliest stages of disease by identifying metastatic potential. 
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 Figure Legends 
Figure 1 - Overview 
Panel A is an overview of somatic alterations detected in matched primary and metastatic tumours 
across a subset of 38 TRACERx Renal patients. The top panel shows the proportion of clonal and 
subclonal alterations. In the middle panel alterations in primary tumours are indicated in a lighter 
shade of colour, those in metastases in darker. Clonal alterations are shown as rectangles and 
subclonal alterations as triangles. Parallel evolution is indicated in orange with a split indicating 
multiple events. Abbreviation for tumour sites: P - primary; TT - tumour thrombus; AD - adrenal gland, 
indirect metastasis; AD(D) – direct invasion of adrenal gland; AD(CL) – contralateral adrenal gland; 
Renal(CL) – contralateral kidney; Pr – perirenal invasiona; Pf – peri-nephric fat and gerota fascia 
invasion. Panel B shows the number of clonal and subclonal somatic alterations in primary and 
metastatic tumours. Panel C shows the number of somatic alterations 1) detected in both primary 
tumour and the matched metastatic tumour; 2) detected in primary tumour but not the matched 
metastatic tumour and 3) detected in metastatic tumour but not the matched primary tumour. Panel 
D shows the proportions of synchronous and metachronous metastatic tumours profiled in the 
TRACERx Renal, HUC and MSK cohorts. Panel E shows the range of the metastatic sites sampled across 
the TRACERx, HUC and MSK cohorts. The total number of metastases sampled (n), and the number 
from each study (Tx represents TRACERx Renal; HUC and MSK are extension cohorts) are shown in 
brackets. 
 
Figure 2 – Characterisation of metastasising clone(s) 
Panel A illustrates the method used to categorising tumour clones. Panel B shows four violin plots 
summarising (starting top left and working clockwise): i) non-synonymous mutation count, ii) wGII, iii) 
ploidy and iv) Ki67. Values are compared between tumour clones “not selected” and “selected” for 
metastasis, with all region/clone values plotted per tumour (excluding MRCA “maintained” clones – 
see STAR methods). A linear mixed effect (LME) model was used to determine significance, to account 
for the non-independence of multiple observations from individual tumours. Panel C shows for each 
driver event the proportion of times it was observed in “not selected” and “selected” clones, for 
TRACERx, HUC and MSK cohorts. The far right panel shows the log10 p-value for each event, for 
enrichment in “selected” versus “not selected” clones, testing using a binomial test with meta-analysis 
conducted using Fisher's method of combining p values from independent tests, and p-values 
corrected for multiple testing using Benjamini–Hochberg procedure. Panel D shows overall survival 
hazard ratios for events with P<0.05 in panel C analysis. Data is shown for TRACERx and HUC cohorts 
separately, with the circle representing the hazard ratio value, and lines corresponding to the 95% 
confidence interval estimate.  Panel E shows overall survival results for TRACERx and HUC cohorts 
(combined), split into two groups based on SCNA status at chr 9p21.3 (either copy number loss at chr 
9p21.3, or normal wildtype copy number). 
 
Figure 3 – Tumour thrombus 
Figure 3 shows tumour thrombus (TT) driver trees with primary clones in the bottom panel; level I, 
level II, level III and level IV tumour thrombus clones in light green, blue, orange and red, respectively. 
Tumour TNM stage and driver events leading to TT are annotated. Where no uniquely identifiable 
primary clone was found to seed the TT, a dotted circle is used to represent the notional seeding clone 
at the TT level. Length of branches connecting clones is not informative.  
 
Figure 4 – Lymph node and distant metastases 
 
 Panel A shows driver trees and the clinical course for cases with lymph node and distal metastases. 
Cases were grouped into those with “rapid progression” and “attenuated progression”.  Annotated 
for each case are the primary tumour evolutionary subtype, primary tumour ITH/wGII classification, 
select driver events on the tree (VHL, BAP1, PBRM1, MTOR, SETD2, TSC1, TSC2, chr 9p loss and chr 
14q loss). Metastasis-seeding subclones and any subclones private to metastasis are highlighted in 
blue. Clinical course is shown from the time of nephrectomy to death or last follow up. Pattern of 
disease progression is classified as multiple new metastases (multiple circles), solitary new metastasis 
(single circle) and progression of existing metastases (“PD”). Progression and follow up times are 
shown in months. Systemic treatments are indicated. Synchronous and metachronous metastatic sites 
are listed under corresponding time points. Profiled metastases are highlighted in blue boxes. 
Abbreviation for tumour sites: P - primary; TT - tumour thrombus; AD - adrenal gland; AD(D) – direct 
invasion of adrenal gland; AD(CL) – contralateral adrenal gland; Renal(CL) – contralateral kidney; Pr – 
perirenal invasion; Pf – peri-nephric fat and gerota fascia invasion. Panel B shows the number of cases 
with “rapid progression” or “attenuated progression” in each evolutionary subtype.  Panel C shows 
the maximum wGII and ITH in cases with “rapid progression” and “attenuated progression”. 
 
Figure 5 – Latent metastases 
Panel A shows the distribution of times from nephrectomy to metastasis resection, split by site of 
metastasis. The circle represents the median value, and grey lines depicts the median average 
deviation (MAD) value (i.e. plus/minus one MAD). Far right in brackets are the range [min to max] 
values. Panel B shows wGII values per region split by site of metastasis. All regions are shown per 
metastasis, and a linear mixed effect (LME) model was used to determine significance (for pancreas 
versus all other), to account for the non-independence of multiple observations from individual 
tumours. Panel C shows fishplot progression patterns for the three cases (SP006, SP023, SP058) with 
latent pancreatic metastases.  
 
Figure 6 – Spatial resolution of metastases through post-mortem sampling  
Figure 6 shows cases K548 (top) and K489 (bottom) which were sampled at post-mortem with the 
extent of sampling and the clinical course shown.  Metastatic progression is illustrated using fish plots 
with the select driver events annotated (VHL, BAP1, PBRM1, MTOR, SETD2, TSC1, TSC2, chr 9p loss 
and chr 14q loss).  Metastasising clone colour matches that of the corresponding metastatic site.  
 
Figure 7 
  
Summary figure describing key conclusions from the study. 
 
  
 Supplementary figure legends 
 
Figure S1: Consort diagram for the selection of the metastatic samples.  
Related to Star methods. 
 
Figure S2: Driver events in HUC and MSK cohorts.  
Figure S2 shows driver mutations and driver SCNAs detected in matched primary and metastatic 
tumours in HUC (panel A) and MSK (panel B) cohorts. Clonal alterations are shown as rectangles and 
subclonal alterations as triangles. Parallel evolution is indicated in orange with a split indicating 
multiple events. Related to Figure 1 
 
Figure S3: Analysis of tumour thrombus.  
Figure S3 Panel A shows the survival analysis for cases where tumour thrombus had early (Group 
C1_TT_early, from founding most recent common ancestor clone) or late (Group C2_TT_late, from a 
later subclone) evolutionary divergence. Survival probability is measured as cancer related death 
P=0.018 (log-rank test). Panel B shows Ki67 proliferation index data (mean % of cells staining positive 
for Ki67 across all primary tumour regions) for cases presenting with and without TT. Panel C shows 
cases with TT and distal metastases. Related to Figure 3. 
 
Figure S4: Fish-plot summary of selected cases.  
Figure S4 shows 2 example cases with distal metastases. Diagrams of the primary tumour and the 
involved tissue sites are illustrated. Fishplots are used to show disease evolution. Driver events are 
annotated on each fishplot. Related to Figure 4 
 
Figure S5: Driver tree for case SP58.  
Related to Figure 5. 
 
Table S1 Clinical and tumour characteristics of TRACERx, HUC and MSK Primary-Met pair patients, 
and evolutionary subtypes, progression patterns, treatment of disease and survival outcomes of 
TRACERx and PEACE patients.  
Related to Figure 1, Figure 4 and Figure 6. 
 
Table S6 Details of custom driver panels (v3, v5 and v6) and somatic alterations in TRACERx cohort.  
Related to Figure 1 and Star methods. 
 
 
 
  
 STAR Methods 
Contact for reagent and resource sharing 
Further information and requests for resources and reagents should be directed to and will be fulfilled 
by the Lead Contact, Charles Swanton (Charles.swanton@crick.ac.uk). 
Experimental model and subject details 
  
Patients were recruited into TRACERx Renal, an ethically approved prospective cohort study (National 
Health Service Research Ethics Committee approval 11/LO/1996). The study sponsor is the Royal 
Marsden NHS Foundation Trust. The study is coordinated by the Renal Unit at the Royal Marsden 
Hospital NHS Foundation Trust. The study is open to recruitment at the following sites: Royal Marsden 
Hospital NHS Foundation Trust, Guy’s and St Thomas’ Hospital NHS Foundation Trust, Royal Free 
Hospital NHS Foundation Trust and Western General Hospital (NHS Lothian). Patients were recruited 
into the study according to the following eligibility criteria: 
Inclusion criteria 
●   Age 18- years or older 
●   Patients with histologically confirmed renal cell carcinoma, or suspected renal cell 
carcinoma, proceeding to nephrectomy/metastectomy 
●   Medical and/or surgical management in accordance with national and/or local 
guidelines 
●   Written informed consent (permitting fresh tissue sampling and blood collection; 
access to archived diagnostic material and anonymised clinical data) 
Exclusion criteria 
●   Any concomitant medical or psychiatric problems which, in the opinion of the 
investigator, would prevent completion of treatment or follow-up 
●   Lack of adequate tissue 
Further eligibility criteria were applied to the cohort presented in this paper (it therefore follows that 
these patients do not have consecutive study ID numbers from 001 to 100): 
●     Confirmed histological diagnosis of clear cell renal cell carcinoma. 
●   No family history of renal cell carcinoma. 
 ●   No known germline renal cell carcinoma predisposition syndrome (including VHL). 
●   At least three primary tumour regions available for analysis. 
The cohort was representative of patients eligible for curative or cytoreductive nephrectomy.   Full 
clinical characteristics are provided in Table S1. Demographic data include: Sex, Age and Ethnicity. 
Clinical data include: Presenting symptoms, Smoking status, BMI, History of Previous RCC, Family 
History of RCC, Bilateral or Multi-focal RCC, Neoadjuvant therapy (6 patients received systemic 
therapy prior to nephrectomy).  Histology data include: overall TNM Stage (based on Version 7 
classification), Location of nephrectomy, Number of harvested and involved lymph nodes, presence 
of Microvascular Invasion, presence of Renal Vein Invasion, presence of IVC tumour thrombus, Size of 
primary tumour, Leibovich score, Fuhrman Grade, Time to nephrectomy (days). Clinical status of 
patients included: Relapse -free survival (months), Total follow up (months), Survival Outcome.  
Extension cohort of primary and metastatic (P-M) pairs was accessed under the approval of Basque 
Country Research Ethics Committee, Hospital Universitario Cruces (Ref CEIC-Euskadi PI2015101). 
Post-mortem sampling was performed in the context of the PEACE study (National Health Service 
Research Ethics Committee approval 13/LO/0972/AM05); 
https://clinicaltrials.gov/ct2/show/NCT03004755. 
 
Method details 
  
Sample collection (TRACERx cohort and post-mortem sampling) 
All surgically resected specimens were reviewed macroscopically by a pathologist to guide multi-
region sampling for this study and to avoid compromising diagnostic requirements.  Tumour 
measurements were recorded and the specimen were photographed before and after sampling. 
Primary tumours were dissected along the longest axes and spatially separated regions sampled from 
the “tumour slice” using a 6 mm punch biopsy needle. The punch was changed between samples to 
avoid contamination. The total number of samples obtained reflects the tumour size with a minimum 
of 3 biopsies that are non-overlapping and equally spaced.  However, areas which are obviously 
 fibrotic or haemorrhagic are avoided during sampling and every attempt is made to reflect 
macroscopically heterogeneous tumour areas. Primary tumour regions are labelled as R1, R2, R3…and 
locations are recorded. Normal kidney tissue was sampled from areas distant to the primary tumour 
and labelled N1.  Each biopsy was split into two for snap freezing and formalin fixing respectively, such 
that the fresh frozen sample has its mirror image in the formalin-fixed sample which is subsequently 
paraffin embedded. Fresh samples were placed in a 1.8 ml cryotube and immediately snap frozen in 
liquid nitrogen for >30 seconds and transferred to -80 C for storage. Peripheral blood was collected at 
the time of surgery and processed to separate buffy coat. 
Nucleic acid isolation from tissue and blood (TRACERx and PEACE cohorts) 
DNA and RNA were co-purified using the AllPrep DNA/RNA mini kit. (Qiagen).   Briefly, a 2mm3 piece 
of tissue was added to 900ul of lysis buffer and homogenised for five seconds using the TissueRaptor 
(Qiagen) with a fresh homogenisation probe being used for each preparation.  Each lysate was applied 
to a QiaShredder (Qiagen) and then sequentially purified using the DNA and RNA columns according 
to the manufacturers protocol. Germline control DNA was isolated from whole blood using the DNeasy 
Blood and Tissue kit (Qiagen) according to the manufacturers protocol. DNA quality and yield was 
measured and accessed using the TapeStation (Agilent) and Qubit Fluorometric quantification 
(ThermoFisher Scientific). 
 
Purification of DNA from Formalin Fixed Paraffin Embedded (FFPE) tissue 
For a minority of TRACERx Renal cases (n=8), tumour material was obtained from FFPE material (Table 
S5). An H&E section from all patient FFPE blocks is reviewed by a pathologist and tumour rich regions 
are identified for DNA purification.  Either a 20uM sections is cut and the area of interest scraped from 
the slide using a blade alternatively a 2mm core is directly punched from the block.  DNA is purified 
using the GeneRead DNA FFPE kit (Qiagen) with yields and quality being determined by Qubit 
quantification and TapeStation analysis. 
  
 
Micro-dissection and nucleic acid isolation (HUC extension cohort)  
H&E slides from each case were annotated by pathologists for regions of interest (ROI).  Multiple ROIs 
within the primary tumour were selected on the bases of good tissue preservation avoiding areas of 
necrosis and haemorrhage, and to reflect microscopically distinct areas with regards to grade (high vs 
low) and morphology (clear vs. granular/eosinophilic), and sarcomatoid differentiation, where 
present, as well as areas of normal tissue.  The annotated H&E was then used as a reference to guide 
the dissection of ROIs from serial sections. All tissue sections were cut to 10 µm thickness and 
deparaffinized with three, five minute incubations in xylene prior to dissection using the alpha AVENIO 
Millisect System (Roche Diagnostics, Indianapolis, IN) (Adey et al., 2013). The milling tip blade size for 
the dissection was selected based on the estimated area of the ROI, where small ROIs less than 
200mm2 used small blade sizes (200 or 400µm) and ROIs larger than 200mm2 used larger blade sizes 
(800 µm).  The milling buffer for all dissections was 1x TE buffer with 2% SDS, pH 7.5.  Genomic DNA 
was isolated from each of the dissected FFPE tissue samples using a High Pure FFPE DNA Isolation kit 
(Roche). 
  
Methylation specific PCR 
Methylation of the VHL promoter was detected after bisulphite treatment of 500ng of patient DNA 
using the EZ DNA Methylation-Direct kit (Zymo Research).  Bisulphite treated DNA was amplified in 
the PCR using methylation specific oligonucleotides (oligonucleotide sequences are detailed in Table 
S6), followed by Big Dye terminator Sanger sequencing.  Methylation was confirmed by comparing 
and contrasting patient tumour and normal renal tissue for methylation protected CpG sequences.   
  
Regional staining by Immunohistochemistry and Digital Image Analysis of Ki67 
 Tissue sections of 4µm were mounted on slides and immunohistochemical staining for Ki67 was 
performed using a fully automated immunohistochemistry (IHC) system and ready-to-use optimized 
reagents according to the manufacturer´s recommendations (Ventana Discovery Ultra, Ventana, 
Arizona, USA). Primary antibody used was rabbit anti-Ki67 (AB16667, Abcam, Cambridge, UK) and 
secondary antibody was Discovery Omnimap anti-rabbit HRP RUO (760-4311, Roche, Rotkreuz, 
Switzerland). DAB kit was Discovery Chromomap DAB RUO (760-4311, Roche). After IHC procedure, 
slides were first evaluated for Ki67 staining quality using mouse intestine tissue as positive control. 
Regions containing tumour tissue were identified and marked by a pathologist and subsequently 
scanned in brightfield at 20x magnification using Zeiss Axio Scan.Z1 and ZEN lite imaging software (Carl 
Zeiss Microscopy GmbH, Jena, Germany). Digital images were then subjected to automated image 
analysis using StrataQuest version 5 (TissueGnostics, Vienna, Austria) for Ki67 quantification. Three 
different gates were set to quantify low, medium and high intensity DAB staining which corresponded 
to Ki67 expression levels. Results were depicted as total percentage of Ki67-positive nuclei.   
Flow Cytometry Determination of DNA Content (FACS) 
Fresh frozen tumour tissue samples, approximately 4mm3 in size, were mechanically disrupted and 
incubated in 2ml of 0.5% pepsin solution (Sigma, UK) at 37 ºC for 40 minutes to create a suspension 
of nuclei. The nuclei were washed with phosphate-buffered saline (PBS) and then fixed with 70% 
ethanol for a minimum of 90 minutes. The nuclei were washed again with PBS and stained with 200μl 
of propidium iodide (50μg/ml) overnight. Flow cytometric analysis of DNA content was performed 
using the LSR Fortessa Cell Analyzer (Becton Dickinson, San Jose, USA), BD Facs Diva™ software and 
FlowJo software (FlowJo LLC, Oregon, USA. A minimum of 10,000 events were recorded (typically up 
to 20,000 and up to 100,000 in complex samples). Analysis was performed using methods derived 
from the European Society for Analytical Cellular Pathology DNA Consensus in Flow Cytometry 
guidelines. Gating of forward and side scatter was applied to exclude debris and cell clumping. 
Samples with <7,500 events after gating were excluded from further analysis. The coefficient of 
variation (CV) was measured on each G1 peak. Samples with a CV>10% were excluded from further 
 analysis. Each tumour sample was assumed to contain normal cells to act as internal standard. Where 
possible the position of the diploid peak was calculated with reference to the peak of diploid cells in 
a case matched normal tissue sample. The DNA index (DI) of any aneuploid peak present was 
calculated by dividing the G1 peak of the aneuploid population by the G1 peak of the normal diploid 
cells.  Diploid samples were defined as having DI of 1.00. Any additional peak was defined as 
aneuploid. A tetraploid peak was defined as having a DI of 1.90-2.10 and containing >15% of total 
events unless a second peak corresponding to G2 was clear on the histogram. Similarly, aneuploid 
peaks near to G1 (DI 0.90-1.10) were only considered if there was a clear second peak containing >15% 
of total events.  
Detection of allelic imbalance at the HLA locus 
Allelic imbalance was detected using two polymorphic Sequence-Tagged Site (STR) markers located 
on the short arm of chr 6, close to the HLA locus - (D6S248 and ATA12D05), six STR markers located 
downstream of the HLA locus on the short arm of chr 6p - (D6S1960, GATA143B11, D6S1714, D6S1573, 
D6S438 and D6S257), and six STR markers located upstream of the HLA locus on the short arm of chr 
6p – (D6S410, D6S2257, D6S1034, D6S202, D6S1617, D6S1668). 20ng of patient germline and tumor 
region DNA was amplified using the PCR. The PCR comprised of denaturing at 950C for 5mins, then 35 
cycles of denaturing at 950C for 1min, followed by an annealing temperature of 550C for 1min, 720C 
for 1min and then a PCR extension at 720C for 10min. PCR products were separated on the ABI 3730xl 
DNA analyzer. Fragment length and area under the curve of each allele was determined using the 
Applied Biosystems software GeneMapper v5. When two separate alleles were identified for a 
particular marker, the fragments could be analyzed for allelic imbalance using the formula 
(Atumor/Atumor)/(Anormal/Anormal). The output of this formula was defined as the normalized 
allelic ratio.  
 
Targeted Driver Panel (DP) design and validation 
 Driver gene panels (Panel_v3, Panel_v5 and Panel_v6) were used in this study. Panel_v3 was designed 
in 2014, including 110 putative driver genes. Panel_v5 and Panel_v6 were designed in 2015, including 
119 and 130 putative driver genes respectively. Driver genes were selected from genes that were 
frequently mutated in TCGA (accessed in April 2015) or highlighted in relevant studies (Arai et al., 
2014; Sato et al., 2013; Scelo et al., 2014). Only alterations in driver genes represented in all three 
panels were considered in the overall driver mutation analyses.  All panels targeted potential driver 
SCNA regions. To prevent inter-patient samples swaps, we included the 24 SNPs that were previously 
identified by Pengelly et al in Panel_v5 and Panel_v6. Details of the 3 panels can be found in 
Supplementary table (Table S8). 
 
Driver Panel Library Construction and Targeted Sequencing 
Following isolated gDNA QC, depending on the available yield, samples were normalised to either 1-3 
µg or 200 ng for the Agilent SureSelectXT Target Enrichment Library Protocol; standard or low input 
sample preparation respectively. Samples were normalised using a 1X Low TE Buffer. Samples were 
sheared to 150-200bp using a Covaris E220 (Covaris, Woburn, MA, USA), following the run parameters 
outlined in the Agilent SureSelectXT standard 3 µg and low input 200 ng DNA protocols. Library 
construction of samples was then performed following the SureSelectXT protocols, using 6 pre-
capture PCR cycles for the standard input samples and 10 pre-capture PCR cycles for the 200 ng low 
input samples. Hybridisation and capture were performed for each individual sample using the Agilent 
custom Renal Driver Panel target-specific capture library (versions 3, 5 & 6). The same version of the 
capture library being used for all samples from the same patient case. Captured SureSelect-enriched 
DNA libraries were PCR amplified using 14 post-capture PCR cycles in PCR reactions that included the 
appropriate indexing primer for each sample. Amplified, captured, indexed libraries passing final QC 
on the TapeStation 4200 were normalised to 2nM and pooled, ensuring that unique indexes were 
allocated to all final libraries (up to 96 single indexes available) in the pool. QC of the final library pools 
was performed using the Agilent Bioanalyzer High Sensitivity DNA Assay. Library pool QC results were 
 used to denature and dilute samples in preparation for sequencing on the Illumina HiSeq 2500 and 
NextSeq 500 sequencing platforms. The final libraries were sequenced 101bp paired-end multiplexed 
on the Illumina HiSeq 2500 and 151bp paired-end multiplexed on the NextSeq 500, at the Advanced 
Sequencing Facility at the Francis Crick Institute. Equivalent sequencing metrics, including per sample 
coverage, was observed between platforms. Single nucleotide variants (SNVs), dinucleotide variants 
(DNVs), small insertions and deletions (INDELs) and somatic copy number alterations (SCNAs) were 
derived from 463 primary tumour regions and 169 matched metastatic regions from 56 primary-
metastasis pairs in 38 patients (with some patients providing multiple metastases, Figure S1, Figure 
1A). Median sequencing coverage was 613x (range 166-1479x) across primary tumour regions and 
567x (range 273-2661x) across metastatic regions. 
 
Targeted DP library construction and sequencing (HUC cohort) 
DP targeted hybrid-capture panel- Solution-based hybridization capture probes (Roche Sequencing 
Solutions) were selected from a genome-wide database of pre-scored probes, which varied in size 
from 50 to 100 nucleotides. Probes were filtered for repetitiveness in the human genome by building 
a 15-mer histogram from the entire human genome, and then calculating the average 15-mer 
frequency of the probe by sliding a 15 bp window across the length of each probe. Probes with a score 
greater than 100 were filtered as repetitive. The remaining probes were scored for uniqueness in the 
human genome, using SSAHA (http://www.sanger.ac.uk/science/tools/ssaha). A match in the genome 
was defined as any 30-mer match in the genome, allowing up to 5 mismatches or indels along the 
length of the match. Additional scoring parameters included penalties for simple sequence repeats 
and penalties for deviation from a target Tm of 80 C. Target regions of interest were increased to a 
minimum size of 100 bp, and then tiled with an average overlap of 35 bp, allowing the probes to 
overhang the ends of the target regions. These tiled probes were selected from the aforementioned 
pre-scored database of probes by choosing the best scoring probe starting in a 15 bp window, moving 
20 bp in the 3’ direction, and repeating. Probes were allowed to have up to 20 possible matches in the 
 genome, though for this panel 99.5% of the probes had 5 or fewer matches. Selected probe sequences 
were manufactured into biotinylated sequence capture probe pools by Roche Sequencing Solutions – 
Madison. 
Library construction. Libraries were constructed using the SeqCap EZ HyperCap Workflow User’s 
Guide, v1.0 (Roche Sequencing Solutions). The extracted DNA was enzymatically fragmented using the 
KAPA HyperPlus library prep kit according to manufacturer’s instructions (Roche Sequencing 
Solutions).  Fragmentation time for DNA isolated from FFPE was linked to the mass of input DNA, and 
varied from 12 to 22 minutes depending on input amount (10 to 100 ng). To increase the efficiency of 
library prep, adapter volume was reduced to 3 l and the adapter ligation reaction was extended to 3 
hours at 20oC for cases with 100ng of input DNA, and at 16 hours at 16oC for libraries with less than 
100ng of input DNA.  
Sequencing- Captured samples were pooled following post-capture amplification, and sequenced 
using an Illumina HiSeq 2500 instrument.  Dual HiSeq SBS v4 (Illumina) runs at 101 base-paired-end 
reads generated the data for analysis. 
 
SNV, and INDEL calling from multi-region DP sequencing 
Paired-end reads (2x100bp) in FastQ format sequenced by Hiseq or NextSeq were aligned to the 
reference human genome (build hg19), using the Burrows-Wheeler Aligner (BWA) v0.7.15. with seed 
recurrences (-c flag) set to 10000  (Li and Durbin, 2009). Intermediate processing of Sam/Bam files 
was performed using Samtools v1.3.1 and deduplication was performed using Picard 1.81 
(http://broadinstitute.github.io/picard/) (Li and Durbin, 2009). Single Nucleotide Variant (SNV) calling 
was performed using Mutect v1.1.7 and small scale insetion/deletions (INDELs) were called running 
VarScan v2.4.1 in somatic mode with a minimum variant frequency (--min-var-freq) of 0.005, a tumour 
purity estimate (--tumor-purity) of 0.75 and then validated using Scalpel v0.5.3 (scalpel-discovery in - 
-somatic mode) (intersection between two callers taken)(Cibulskis et al., 2013; Fang et al., 2016; 
Koboldt et al., 2009). SNVs called by Mutect were further filtered using the following criteria: i) ≤5 
 alternative reads supporting the variant and variant allele frequency (VAF) ≤ 1% in the corresponding 
germline sample, ii) variants that falling into mitochondrial chr, haplotype chr, HLA genes or any 
intergenic region were not considered, iii) presence of both forward and reverse strand reads 
supporting the variant, iv) >5 reads supporting the variant in at least one tumour region of a patient, 
v) variants were required to have cancer cell fraction (CCF)>0.5 in at least one tumour region (see 
Subclonal deconstruction of mutations section for details of CCF calculation) , vi) variants were 
required to have CCF>0.1 to be called as present in a tumour region, vii) sequencing depth in each 
region need to be >=50 and ≤3000. Finally, suspected artefact variants, based on inconsistent allelic 
frequencies between regions, were reviewed manually on the Integrated Genomics Viewer (IGV), and 
variants with poorly aligned reads were removed. Dinucleotide substitutions (DNV) were identified 
when two adjacent SNVs were called and their VAFs were consistently balanced (based on proportion 
test, P>=0.05). In such cases the start and stop positions were corrected to represent a DNV and 
frequency related values were recalculated to represent the mean of the SNVs. To reduce sequencing 
artefacts from FFPE samples, we further filtered out variants that were significantly enriched for 
presence in FFPE compared with fresh frozen samples (Fisher’s exact test, P<0.001). Variants were 
annotated using Annovar (Wang et al., 2010).  Variants were annotated using Annovar (Wang et al., 
2010). Deleterious mutations were defined if two out of three algorithms - SIFT, PolyPhen2 and 
MutationTaster - predicted the mutation as deleterious. Individual tumour biopsy regions were judged 
to have failed quality control and excluded from analysis based on the following criteria: i) sequencing 
coverage depth below 100X, ii) low tumour purity such that copy number calling failed. Mutations 
detected in high-confidence driver genes (VHL, PBRM1, SETD2, PIK3CA, MTOR, PTEN, KDM5C, CSMD3, 
BAP1, TP53) were defined as driver mutations.  
 
SCNA calling from multi-region DP sequencing 
To estimate somatic copy number alterations, CNVkit v0.7.3 was performed with default parameter 
on paired tumour-normal sequencing data (Talevich et al., 2016). Outliers of the derived log2-ratio 
 (logR) calls from CNVkit were detected and modified using Median Absolute Deviation Winsorization 
before case-specific joint segmentation to identify genomic segments of constant logR (Nilsen et al., 
2012).  Tumour sample purity, ploidy and absolute copy number per segment were estimated using 
ABSOLUTE v1.0.6 (Carter et al., 2012). In line with recommended best practice all ABSOLUTE solutions 
were reviewed by 3 researchers, with solutions selected based on majority vote. Copy number 
alterations were then called as losses or gains relative to overall sample wide estimated ploidy. Arm 
gain or loss was called when >50% of the chromosomal have copy number gain or loss. Driver copy 
number was identified by overlapping the called somatic copy number segments with putative driver 
copy number regions identified by Beroukhim and colleagues (Beroukhim et al., 2009). For a subset of 
TRACERx Renal patients, we compared SCNA calls between targeted panel and WGS datasets, and 
SCNA concordance was 87% (Companion paper, Turajlic et al., 2018). The average proportion of the 
genome with aberrant copy number, weighted on each of the 22 autosomal chromosomes, was 
estimated as the weighted genome instability index (wGII).  
 
MSK validation cohort 
Matched tumour and normal aligned sequencing files (BAM format) for the MSK cohort were obtained 
directly from the authors (Becerra et al., 2017) and were then converted into FASTQ format files using 
bam2fastq in bedtools package (Quinlan and Hall, 2010). SNVs, INDELs and SCNAs were called using 
the same methods as TRACERx Renal data (STAR Methods: SNV, and INDEL calling from multi-region 
DP sequencing, SCNA calling from multi-region DP sequencing). Of the 49 cases with ccRCC histology, 
15 cases (Pair 8, Pair 9, Pair 13, Pair 17, Pair 22, Pair 35, Pair 38, Pair 42, Pair 43, Pair 44, Pair 48, Pair 
52, Pair 56, Pair 58, Pair 59) were excluded from the study as the ABSOLUTE v1.0.6 algorithm failed to 
find a stable SCNA solution. Clonality of SNVs and SCNAs were estimated using ABSOLUTE v1.0.6. 
Cancer cell fraction for INDELs were calculated using method described in STAR Methods: Subclonal 
deconstruction of mutations. INDELs with CCF>0.5 were called clonal. ITH index for each patient was 
 calculated as the measure of intratumour heterogeneity (ITH index = # subclonal drivers / # clonal 
drivers). 
 
Quantification and statistical analysis 
  
R 3.3.2 was used for all statistical analyses. We tested for difference in driver event count between 
primary and metastatic samples using linear regression, including biopsy number per sample as an 
independent term in the regression model. The comparison of wGII, DNA index and Ki67 scores 
between “not selected” and “selected” clones was assessed using region values per case. Regions 
were classified as being within “not selected” or “selected” clones based on the clustering solution for 
each tumour. Regions found to be only within the founding MRCA clone, or polyclonal with both “not 
selected” and “selected” clones, were excluded. The comparison of non-synonymous mutation counts 
between “not selected” and “selected” clones was based directly on clonal clustering solution 
obtained for each case, again with founding MRCA clones excluded. For all “not selected” versus 
“selected” comparisons a linear mixed effect (LME) model was used to determine significance, to 
account for the non-independence of multiple observations from individual tumours. The comparison 
of maximum wGII (defined as the maximum regional wGII value per primary tumour) between “Rapid” 
and “Attenuated” metastatic progression groups was assessed using Mann-Whitney test. Comparison 
of ITH values (again one score per tumour) between “Rapid” and “Attenuated” metastatic progression 
groups was determined using Mann-Whitney test. The comparison of wGII between pancreatic and 
all other metastatic tissue sites was assessed conducted using region values per case, with significance 
determined using a LME model. 
 
Subclonal deconstruction of mutations 
To estimate the clonality of a mutation in a region, we used the following formula: 
𝑣𝑎𝑓 =
𝐶𝑁𝑚𝑢𝑡  ∗  𝐶𝐶𝐹 ∗  𝑝
𝐶𝑁𝑛  ∗  (1 − 𝑝) +  𝐶𝑁𝑡  ∗  𝑝
 
where 𝑣𝑎𝑓 is the variant allele frequency at the mutation base; 𝑝 is estimated tumour purity; 𝐶𝑁𝑡 and 
𝐶𝑁𝑛 are the tumour locus specific copy number and the normal locus specific copy number which was 
 assumed to be 2 for autosomal chromosomes; and 𝐶𝐶𝐹 is the fraction of tumour cells carrying the 
mutation. Consider 𝐶𝑁𝑚𝑢𝑡 is the number of chromosomal copies that carry the mutation, the possible 
𝐶𝑁𝑚𝑢𝑡 is ranging from 1 to 𝐶𝑁𝑡 (integer number). We then assigned 𝐶𝐶𝐹 with one of the possible 
value: 0.01, 0.02, ..., 1, together with every possible 𝐶𝑁𝑚𝑢𝑡 to find the best fit cancer cell fraction of 
the mutation. Since we focused on driver genes in this study and the accuracy of the estimated CCF is 
limited by the size of the panel, we call mutations with CCF>0.5 as clonal mutations, mutations with 
CCF≤0.5 and CCF>0.1 are subclonal. To determine the clonality of a mutation in a tumour, we ask for 
the mutation to be clonal in all regions in a tumour. Exceptions were made for long INDELs that 
affect >6 bp of the genome, due to VAF under estimation. If a long INDEL is present in all regions of a 
tumour, we called it as clonal. To determine the clonality of a SCNA in a tumour, we ask for the SCNA 
to be presence in all tumour regions, otherwise it is called subclonal.  
  
Driver tree reconstruction 
A matrix with presence and absence of nonsynonymous and synonymous point mutations, DNVs, 
INDELs and arm level SCNAs was created for each tumour, and all the events were clustered based on 
the following rule: a valid cluster has to have at least two arm level SCNAs or one non-synonymous 
mutation. The driver events clusters were then ordered into a clonal hierarchy using TRONCO and 
presented as driver trees (De Sano et al., 2016). 
  
In terms of limitations, we recognise that our Driver Panel phylogenies are based on fewer clonal 
markers, as compared to whole exome or genome derived phylogenetic trees. As a consequence, 
some tumour clones are based on only a limited number of genomic markers, and similarly the 
inferred modes of metastatic seeding (e.g. monoclonal vs polyclonal) are also based on a limited set 
of markers. However, two contingency measures are in place to mitigate against phylogenetic 
misconstruction: i) ultra-deep 500x sequencing coverage, which ensures stably derived cancer cell 
 fraction estimates, ii) a bespoke gene panel which is enriched for driver events, increasing the 
likelihood that mutational markers are driving genuine clonal expansion.  
 
Enrichment of events in metastases 
All tumour clones were categorised into three groups based on evidence of selection in the 
metastasis/metastases: i) clone that are not selected (“no selection”, defined as subclonal in the 
primary and absent from metastasis), ii) clones that are maintained (“maintained”, defined as the 
most recent common ancestor (MRCA) clones, clonal in both primary and metastasis  ), iii) clones that 
are selected (“selection”, defined as subclonal in the primary and clonal in metastasis; or absent in the 
primary and present in metastasis). In addition, we observed a small number of clones with alternative 
selection patterns: a) being subclonal in both primary and in metastases (i.e. polyclonal metastases), 
which we categorised as “maintained”, and b) being clonal in primary and sublconal in metastases 
categorised as “maintained” c) clonal in primary but absent in metasteses (i.e. illusion of clonality or 
events lost by secondary somatic changes), which we categorised as “no selection”. For each driver 
event (mutational or SCNA), the proportion of times it was found in “not selected”, “maintained” and 
“selected” clones was calculated for each of the TRACERx, HUC and MSK cohorts. For comparison 
purposes, a background null distribution of proportions was determined for both mutations and 
SCNAs, based on all passenger events in each cohort. The proportion of “selected” clones was 
compared to the “not selected” proportion, using a Binomial test, with probability of selection taken 
from the null model, and number of trials based on event counts in each cohort. Meta-analysis across 
the three cohorts was conducted using Fisher's method of combining p values from independent tests, 
and p-values were corrected for multiple testing using Benjamini–Hochberg procedure. 
 
Survival analysis 
 Survival analysis was conducted using the Kaplan-Meier method, with p-value determined by a log-
rank test. Hazard ratio and multivariate analysis adjusting for clinical parameters was determined 
through a Cox proportional hazards model.  
  
Data and Software Availability   
 
Sequencing data that supports this study will been deposited at the European Genome-phenome 
Archive (EGA), which is hosted by the European Bioinformatics Institute (EBI); accession number 
EGAS00001002793. 
Additional resources  
  
Clinical trial registry numbers:  
https://clinicaltrials.gov/ct2/show/NCT03226886;  
https://clinicaltrials.gov/ct2/show/NCT03004755 
 
TRACERx Renal study website, detailing investigators, sponsors and collaborators: 
http://tracerx.co.uk/studies/renal/ 
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Consortium 
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 Experimental Models: Cell Lines 
   
   
   
   
   
Experimental Models: Organisms/Strains 
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This paper Table S6 
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Mutect v1.1.7 Cibulskis et al., 2013 http://archive.broadin
stitute.org/cancer/cg
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VarScan v2.4.1 Koboldt et al., 2009 http://varscan.source
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Scalpel v0.5.3 Fang et al., 2016 https://github.com/ha
nfang/scalpel-
protocol 
Annovar Wang et al., 2010 http://annovar.openb
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ABSOLUTE v1.0.6 Carter et al., 2012 http://archive.broadin
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bedtools package Quinlan and Hall, 2010 http://bedtools.readt
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R package ‘TRONCO’ De Sano et al., 2016 http://www.biocondu
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REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Rabbit monoclonal anti-Snail Cell Signaling Technology Cat#3879S; RRID: 
AB_2255011 
 Mouse monoclonal anti-Tubulin (clone DM1A) Sigma-Aldrich Cat#T9026; RRID: 
AB_477593 
Rabbit polyclonal anti-BMAL1 This paper  N/A 
Bacterial and Virus Strains 
pAAV-hSyn-DIO-hM3D(Gq)-mCherry Krashes et al., 2011 Addgene AAV5; 
44361-AAV5 
 
AAV5-EF1a-DIO-hChR2(H134R)-EYFP Hope Center Viral Vectors 
Core 
N/A 
Cowpox virus Brighton Red BEI Resources NR-88 
Zika-SMGC-1, GENBANK: KX266255 Isolated from patient 
(Wang et al., 2016) 
N/A 
Staphylococcus aureus ATCC ATCC 29213 
Streptococcus pyogenes: M1 serotype strain: strain 
SF370; M1 GAS 
ATCC ATCC 700294 
Biological Samples 
Healthy adult BA9 brain tissue University of Maryland 
Brain & Tissue Bank; 
http://medschool.umarylan
d.edu/btbank/ 
Cat#UMB1455 
Human hippocampal brain blocks New York Brain Bank http://nybb.hs.colum
bia.edu/ 
Patient-derived xenografts (PDX) Children's Oncology 
Group Cell Culture and 
Xenograft Repository 
http://cogcell.org/ 
Chemicals, Peptides, and Recombinant Proteins 
MK-2206 AKT inhibitor Selleck Chemicals S1078; CAS: 
1032350-13-2 
SB-505124 Sigma-Aldrich S4696; CAS: 
694433-59-5 (free 
base) 
Picrotoxin Sigma-Aldrich P1675; CAS: 124-
87-8 
Human TGF-β  R&D 240-B; GenPept: 
P01137 
Activated S6K1  Millipore Cat#14-486 
GST-BMAL1  Novus  Cat#H00000406-
P01 
Critical Commercial Assays 
EasyTag EXPRESS 35S Protein Labeling Kit Perkin-Elmer NEG772014MC  
CaspaseGlo 3/7 Promega G8090 
TruSeq ChIP Sample Prep Kit Illumina IP-202-1012 
Deposited Data 
Raw and analyzed data  This paper GEO: GSE63473 
B-RAF RBD (apo) structure This paper PDB: 5J17 
Human reference genome NCBI build 37, GRCh37 Genome Reference 
Consortium 
http://www.ncbi.nlm.
nih.gov/projects/gen
ome/assembly/grc/h
uman/ 
Nanog STILT inference This paper; Mendeley 
Data 
http://dx.doi.org/10.1
7632/wx6s4mj7s8.2 
 Affinity-based mass spectrometry performed with 57 
genes 
This paper; and Mendeley 
Data 
Table S8; 
http://dx.doi.org/10.1
7632/5hvpvspw82.1 
Experimental Models: Cell Lines   
Hamster: CHO cells  ATCC CRL-11268 
D. melanogaster: Cell line S2: S2-DRSC Laboratory of Norbert 
Perrimon 
FlyBase: 
FBtc0000181 
Human: Passage 40 H9 ES cells  MSKCC stem cell core 
facility 
N/A 
Human: HUES 8 hESC line (NIH approval number 
NIHhESC-09-0021) 
 
HSCI iPS Core hES Cell Line: 
HUES-8 
Experimental Models: Organisms/Strains  
C. elegans: Strain BC4011: srl-1(s2500) II; dpy-
18(e364) III; unc-46(e177)rol-3(s1040) V. 
Caenorhabditis Genetics 
Center 
WB Strain: BC4011; 
WormBase: 
WBVar00241916 
D. melanogaster:  RNAi of Sxl: y[1] sc[*] v[1]; 
P{TRiP.HMS00609}attP2 
Bloomington Drosophila 
Stock Center 
BDSC:34393; 
FlyBase: 
FBtp0064874 
S. cerevisiae:  Strain background: W303 ATCC ATTC: 208353 
Mouse: R6/2: B6CBA-Tg(HDexon1)62Gpb/3J The Jackson Laboratory JAX: 006494 
Mouse: OXTRfl/fl: B6.129(SJL)-Oxtrtm1.1Wsy/J The Jackson Laboratory RRID: 
IMSR_JAX:008471 
Zebrafish: Tg(Shha:GFP)t10:  t10Tg Neumann and Nuesslein-
Volhard, 2000 
ZFIN: ZDB-GENO-
060207-1 
Arabidopsis: 35S::PIF4-YFP, BZR1-CFP Wang et al., 2012 N/A 
Arabidopsis: JYB1021.2: 
pS24(AT5G58010)::cS24:GFP(-G):NOS #1 
NASC NASC ID: N70450 
Oligonucleotides 
siRNA targeting sequence: PIP5K I alpha #1: 
ACACAGUACUCAGUUGAUA 
 
This paper N/A 
Primers for XX, see Table SX This paper N/A 
Primer: GFP/YFP/CFP Forward: 
GCACGACTTCTTCAAGTCCGCCATGCC 
This paper N/A 
Morpholino: MO-pax2a 
GGTCTGCTTTGCAGTGAATATCCAT 
Gene Tools ZFIN: ZDB-
MRPHLNO-061106-
5 
ACTB (hs01060665_g1)  Life Technologies  Cat#4331182 
RNA sequence: hnRNPA1_ligand: 
UAGGGACUUAGGGUUCUCUCUAGGGACUUAG
GGUUCUCUCUAGGGA 
This paper 
 
N/A 
Recombinant DNA 
pLVX-Tight-Puro (TetOn) Clonetech Cat#632162 
Plasmid: GFP-Nito This paper N/A 
cDNA GH111110 Drosophila Genomics 
Resource Center 
DGRC:5666; 
FlyBase:FBcl013041
5 
AAV2/1-hsyn-GCaMP6- WPRE  
 
Chen et al., 2013 
 
N/A 
Mouse raptor: pLKO mouse shRNA 1 raptor Thoreen et al., 2009 Addgene Plasmid 
#21339 
 Software and Algorithms 
Bowtie2 Langmead and Salzberg, 
2012 
http://bowtie-
bio.sourceforge.net/
bowtie2/index.shtml 
Samtools Li et al., 2009 http://samtools.sourc
eforge.net/ 
Weighted Maximal Information Component Analysis 
v0.9 
Rau et al., 2013 https://github.com/C
hristophRau/wMICA 
ICS algorithm This paper; Mendeley 
Data 
http://dx.doi.org/10.1
7632/5hvpvspw82.1 
Other 
Sequence data, analyses, and resources related to 
the ultra-deep sequencing of the AML31 tumor, 
relapse, and matched normal. 
This paper http://aml31.genome
.wustl.edu 
Resource website for the AML31 publication 
 
This paper https://github.com/ch
risamiller/aml31Supp
Site 
 
AB C D E
●●
●Liver (n=3: Tx=1, 
HUC=1, MSK=1)
Lung (n=13:
Tx=1, HUC=6,
MSK=6)
Contralateral kidney 
(n=2:  HUC=1)
● ●
Primary ccRCCs
(n=98: Tx=38, HUC=26,
MSK=34)
Tumour thrombus
(n=25: Tx=25)
●
Lymph node (n=24:
Tx=11, HUC=6, MSK=7)
Adrenal gland (n=20:
Tx=11, HUC=2, MSK=7)
Bone (n=17: 
Tx=5, HUC=4,
MSK=8)
Peri-renal (n=3: Tx=3)
Pancreas (n=3: HUC=3)
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